Temozolomide is additive with cytotoxic effect of irradiation in canine glioma cell lines
Abstract Background Similar to human glioblastoma patients, glial tumours in dogs have high treatment resistance and a guarded prognosis. In human medicine, the addition of temozolomide to radiotherapy leads to a favourable outcome in vivo as well as a higher antiproliferative effect on tumour cells...
Enregistré dans:
Auteurs principaux: | Nina Simona Tresch, Daniel Fuchs, Luca Morandi, Caterina Tonon, Carla Rohrer Bley, Katarzyna J. Nytko |
---|---|
Format: | article |
Langue: | EN |
Publié: |
Wiley
2021
|
Sujets: | |
Accès en ligne: | https://doaj.org/article/c491c22a2201430a9e482953be6be5db |
Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|
Documents similaires
-
MiR-21, miR-34a, miR-125b, miR-181d and miR-648 levels inversely correlate with MGMT and TP53 expression in primary glioblastoma patients
par: Dorota Jesionek-Kupnicka, et autres
Publié: (2019) -
Expresión de O6-metilguanina-ADN-metiltransferasa (MGMT) en pacientes chilenos con glioblastoma multiforme
par: Jiménez,Daniel, et autres
Publié: (2018) -
Lack of Benefit of Extending Temozolomide Treatment in Patients with High Vascular Glioblastoma with Methylated <i>MGMT</i>
par: María del Mar Álvarez-Torres, et autres
Publié: (2021) -
Cyclooxygenase-2 as a biomarker with diagnostic, therapeutic, prognostic, and predictive relevance in small animal oncology
par: Szweda Marta, et autres
Publié: (2020) -
Histone Modification in NSCLC: Molecular Mechanisms and Therapeutic Targets
par: Khuloud Bajbouj, et autres
Publié: (2021)